REVIEW PAPER
Can an adequate diet be helpful in the treatment of psoriasis vulgaris?
1
Zakład Dietetyki i Żywienia Klinicznego, Uniwersytet Medyczny w Białymstoku
Corresponding author
Diana Wasiluk
Zakład Dietetyki i Żywienia Klinicznego, Uniwersytet Medyczny w Białymstoku, ul. Mieszka I 4B, 15-054 Białystok
Zakład Dietetyki i Żywienia Klinicznego, Uniwersytet Medyczny w Białymstoku, ul. Mieszka I 4B, 15-054 Białystok
Med Og Nauk Zdr. 2012;18(4):405-408
KEYWORDS
ABSTRACT
Psoriasis vulgaris is a chronic, remittent, inflammatory skin disease with unknown etiology. The disease affects 2-3% of the population worldwide. It is characterized by an excessive proliferation of epidermal cells and state of inflammation in the dermis. The factors instigating the eruption of the disease are: genetic, immunological, infections, stress, injuries and stimulants. Diet is an environmental factor that may essentially affect the course of the disease. It has been ascertained that diets with low energy supply activate natural anti–inflammatory mechanisms. Overweight patients with psoriasis are
recommended to reduce body weight. The elimination or limitation of the consumption of animal products (vegetarian diet) results in the reduction in the supply of saturated fatty acids. A diet rich in polyunsaturated fatty acids omega – 3, i.e. an increase in the consumption of sea fish (sardine, salmon, mackerel, herring, tuna) alleviates the symptoms of psoriasis.
Patients are recommended to consume large quantities of fresh vegetables and fruits. It seems essential for psoriasis patients to have an appropriate serum concentration of vitamin D3. It has been observed that in patients with confirmed gluten intolerance the application of a gluten–free diet can considerably inhibit the activity of psoriasis. The elimination of the use of stimulants (tobacco, alcohol) is also recommended.
REFERENCES (48)
1.
Jabłońska S, Majewski S. Choroby skóry i choroby przenoszone drogą płciową. Wydanie II, Warszawa PZWL; 2008.
2.
Neneman A, Adamski Z. Aspekty kliniczne i epidemiologiczne zaburzeń ogólnoustrojowych u chorych na łuszczycę. Forum Med Rodz. 2009; 3(6): 447-453.
4.
Henseler T, Christopers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985; 13(3): 450-456.
5.
Lerner MR, Lerner AB. Congenital psoriasis. Report of three cases. Arch Derm. 1972; 105(4): 598-601.
6.
Baran A, Flisiak I, Chodynicka B. Znaczenie wybranych adipokin w łuszczycy. Przegl Dermatol. 2011; 98: 422-428.
7.
Nakajima K. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J Dermatol. 2012; 39(3): 219-24.
8.
Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 2007; 8; 445(7128): 648-51.
9.
Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004; 199(1): 125-130.
10.
Wolters M. Diet and psoriasis: experimental data and clinical evidence. Br J Dermatol. 2005; 153: 706-714.
11.
Rucevic I, Pearl A, Barisic-Drusko V, Adam-Perl M. The role of the low energy diet in psoriasis vulgaris treatment. Col Anrtopoll. 2003; 27: 41-48.
12.
Fraser DA, Thoen J, Reseland JE, Forre O, Kjeldsen-Kragh J. Deceeased CD4+ lymphocyte activation and increased interleukin-4 production in peripheral blood of rheumatoid arthritis patients after acute starvation. Clin Rheumatol. 1999; 18: 394-401.
13.
Naldi L, Parazzini F, Peli L, Chatenouldt L, Cainelli T. Dietary factors and the risk of psoriasis. Results of Italian case-control study. Br J Dermatol. 1996; 134: 101-106.
14.
Gisondi P, Micol Del Giglio, Vincenzo Di Francesco, Zamboni M, Gi¬rolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutrit. 2008; 88(5): 1242-1247.
15.
Ciborowska H, Rudnicka A. Dietetyka. Żywienie zdrowego i chorego człowieka. Wydanie 3. Warszawa: Wydawnictwo PZWL; 2007.
16.
Serwin A. Badania nad gospodarką selenową w łuszczycy. Praca doktorska, AM Białystok, 1999.
17.
Gawęcki J, Hryniewicki L. Żywienie człowieka. Podstawy nauki o ży¬wieniu. T. 1, Warszawa, Wydawnictwo Naukowe PWN; 2010.
18.
Czelej D, Chodorowska G, Wojnowska D. Wpływ diety na przebieg i leczenie łuszczycy. Przeg Dermatol. 2007; 6(94): 701-705.
19.
Serhan C, Krishnamoorthy S, Recchiuti A, Chiang N. Novel anti¬-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem. 2011; 11: 629-647.
20.
Kowal-Bielecka O. Eikozanoidy w patogenezie twardziny układowej. Przegl Reumatol. 2006; 3: 2-31.
21.
Kozłowska U. Capivit hydro Control – preparat zawierający olej z na¬sion ogórecznika, zapobiegający nadmiernej przez naskórkowej utracie wody. Ordynator Lek. 2006; 51: 30-36.
22.
Motta S, Monti M, Sesana S, Mellesi L, Ghidoni R, Caputo R. Abnor¬mality of water barrier function in psoriasis. Role of ceramide fractions. Arch Dermatol. 1994; 130(3): 452-456.
23.
Vahlquist C, Berne B, Boberg M. The fatty-acid spectrum in plasma and adipose tissue in patients with psoriasis. Arch Dermatol Res. 1985; 278(2): 114-119.
24.
Motta S, Sesana S, Monti M, Giuliani A, Caputo R. Interlamellar lipid differences between normal and psoriatic stratum corneum. Acta Derm Venereol. 1994; 186: 131-132.
25.
Kragballe K. Dietary supplementation with a combination of n-3 and n-6 fatty acids (super gamma-oil marine) improves psoriasis. Acta DermVenereol. 1989; 69(3): 265-268.
26.
Logan AC. Omega-3, omega-6 and psoriasis: a different view. Int J Dermatol. 2005; 44: 527-528.
27.
Bjørneboe A, Smith AK, Bjørneboe GE, Thune PO, Drevon CA. Effect of dietary supplementation with n-3 fatty acids on clinical manifestations of psoriasis. Br J Dermatol. 1988; 118: 77-83.
28.
Chalmers RJ, O’Sullivan T, Owen CM, Griffiths CE. A systematic review of treatments for guttate psoriasis. Br J Dermatol. 2001; 145: 891-894.
29.
Ricketts JR, Rothe MJ, Grant-Kels JM. Nutrition and psoriasis. Clin Dermatol. 2010; 28(6): 615-626.
30.
Ziboh VA. Implications of dietary oils and polyunsaturated fatty acids in the management of cutaneous disorders. Arch Dermatol. 1989; 125(2): 241-245.
31.
Schuppan D. Current concepts of celiac disease pathogenesis. Gastroen¬terol. 2000; 119: 234-242.
32.
Guandalini S, Gokhale R. Update on immunologic basis of celiac disease. Curr Opin Gastroenterol. 2002; 18: 95-100.
33.
Woo WK, McMillan SA, Watson RG, McCluggage WG, Sloan JM, McMillan JC. Coeliac disease-associated antibodies correlate with psoriasis activity. Br J Dermatol. 2004; 151(4): 891-894.
34.
Adrych K, Marek IE, Kryszewski AJ. Choroba trzewna u dorosłych – wierzchołek góry lodowej. Wiad Lek. 2006; 59: 5-6.
35.
Michaëlsson G, Gerdén B, Ottosson M, Parra A, Sjöberg O, Hjelmquist G, et al. Patients with psoriasis often have increased serum levels of IgA antibodies to gliadin. Br J Dermatol. 1993; 129: 667-673.
36.
Michaëlsson G, Gerdén B, Hagforsen E, Nilsson B, Pihl-Lundin I, Kraaz W, et al. Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol. 2000; 142: 44-51.
37.
Staberg B, Oxholm A, Klemp P, Christiansen C. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereo1. 1987; 67: 65-68.
38.
Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermato1. 1996; 134: 1070-1078.
39.
Grant WB, Holick ME. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005; 10: 94-111.
40.
Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005; 135: 317-322.
41.
Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007; 85(3): 649-650.
42.
Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatol. 2006; 213(4): 319-326.
43.
Higgins E. Alkohol, smoking and psorasis. Clin Exp Dermatol. 2000; 25: 107-110.
44.
Wolf R, Wolf D, Ruocco V. Alkohol intake and psoriasis. Clin Dermatol. 1999; 17: 423-430.
45.
Chodorowska G, Kwiatek J. Psoriasis and cigarette smoking. Ann UMCS Sect.D. 2004; 59(2): 535-538.
46.
Smith KE, Fenske NA. Cutaneous manifestations of alcohol abuse. J Am Acad Dermatol. 2000; 43: 1-16.
47.
Luty-Frąckiewicz A. Wpływ palenia tytoniu i picia alkoholu na zmiany skórne u pacjentów z łuszczycą zwykłą. Przegl Dermatol. 2003; 90: 275.
48.
Naldi L. Cigarette smoking and psoriasis. Clin Dermatol. 1998; 16: 571-574.
| eISSN: | 2084-4905 |
| ISSN: | 2083-4543 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
